News and Trends 11 Jul 2016
On the way to a ‘Functional’ HIV Cure? Norway Vaccine clears viral load in 88% of Patients
Oslo based Biopharma Bionor has a Phase I results for a HIV vaccine. The vaccine infusion rendered viral presence in 88% of patients undetectable after combination treatments with Celgene‘s enzyme inhibitor, Istodax and standard retroviral drugs. The positive results from the clinical trial REDUC Part B were published in the high impact journal The Lancet HIV. The Norwegian’s proprietary […]